Diabetic Retinopathy Treatment Market Segments, Opportunity, Growth and Forecast by End-Use Industry till 2028
The global Diabetic Retinopathy Treatment market size is expected to reach USD by 14.95 Billion 2028 at a CAGR of 7.10%, according to a new report by Reports and Data. Rising prevalence of chronic conditions such as diabetes, increasing cases of Diabetic Retinopathy Treatment among diabetic patients, and growing preferences for technologically advanced and minimally invasive procedures are among the major factors responsible for the growth of the global Diabetic Retinopathy Treatment market in the upcoming years. Booming geriatric population worldwide and their growing susceptibility to chronic diseases such as diabetes, cardiovascular disorders, and sleep disorders further boost market growth to a significant extent.
Diabetic Retinopathy Treatment is a severe medical
condition in which diabetes affects the eyes. The principal cause of Diabetic
Retinopathy Treatment is damage to the blood vessels of the light-sensitive
tissue of the retina. The most common symptoms of this condition include
blurred vision, fluctuating vision, dark or empty areas in the vision, impaired
color vision, and vision loss. Excessive amount of sugar in blood leads to the
blockage of the tiny blood vessels of the retina and hamper blood supply. Mild-to-moderate
cases of Diabetic Retinopathy Treatment may be treated with the help of
effective diabetes management; however, advanced cases require laser treatment
or surgical procedures.
Get
a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1484
Competitive
Landscape:
The report also covers
SWOT examination and Porter’s Five Forces analysis to offer details about
leading players. The key players in the market are focusing on developing new
strategies such as mergers and acquisition, joint ventures, new product
launches, agreements, and partnerships to retain their market position and
expand their product base.
Leading
companies operating in the market and profiled in the report include:
· Bayer
AG
· Pfizer
Inc
· F.
Hoffmann-La Roche Ltd
· Regeneron
Pharmaceuticals Inc
· Novartis
AG
· Valeant
Pharmaceuticals International Inc
· Abbott
Laboratories Ltd
· Alimera
Sciences Inc
· AmPio
Pharmaceuticals Inc
· Bausch
& Lomb Inc
· Boehringer
Ingelheim GmbH
· iCo
Therapeutics Inc
· Lupin
Ltd
· PAREXEL
International Corp
· Quark
Pharmaceuticals Inc
· Thrombogenic
NV
· Vitreoretinal
Technologies Inc
Request
a customization of the report @ https://www.reportsanddata.com/request-customization-form/1484
Some Key Highlights in the Report:
- Non-proliferative
Diabetic Retinopathy Treatment segment is projected to register the
highest CAGR of 7.5% over the forecast period. Rising prevalence of
non-proliferative Diabetic Retinopathy Treatment among diabetic patients
is one of the most vital factors driving this segment’s growth.
- On
the basis of management, the anti-VEGF segment dominated tin terms of
revenue in 2020. The segment is expected to maintain its dominance
throughout the forecast period, owing to increasing applications of
anti-VEGF drugs including Eylea, Lucentis, Avastin, and Macugen in the
treatment of mild-to-moderate cases of Diabetic Retinopathy Treatment is
one of the key factors accountable for the growth of this segment.
- Among
the various distribution channels, the hospitals segment held the largest
revenue share in the global Diabetic Retinopathy Treatment market in 2020.
Increasing availability of diagnostic instruments in hospitals and
pharmacies worldwide and growing number of treatment procedures for Diabetic
Retinopathy Treatment bolster the growth of this segment.
- The
North America Diabetic Retinopathy Treatment market is the most dominant
regional market in terms of revenue. Growing prevalence of diabetes,
increasing use of anti-VEGF drugs including Avastin, Eylea, and Lucentis
for Diabetic Retinopathy Treatment, rising patient awareness, and the
presence of state-of-the-art healthcare infrastructure in North America
are the primary factors accountable for the regional market growth. The
Asia Pacific market is the fastest-growing regional market and is expected
to display a robust CAGR of 8.3% over the forecast period.
Download
Summary @ https://www.reportsanddata.com/download-summary-form/1484
For the purpose of this report, the global
Diabetic Retinopathy Treatment market is segmented on the basis of type,
disease form, management, distribution channel, and region:
Type (Revenue, USD Billion;
2020-2028)
- Mild
- Moderate
- Severe
Disease Form (Revenue, USD Billion;
2020-2028)
- Proliferative
Diabetic Retinopathy Treatment
- Non-proliferative
Diabetic Retinopathy Treatment
Management (Revenue, USD Billion;
2020-2028)
- Anti-VEGF
- Intraocular
steroid injection
- Laser
surgery
- Vitrectomy
Distribution channel (Revenue, USD
Billion; 2020-2028)
- Eye
clinics
- Hospitals
- Retail
pharmacies
- Online
pharmacies
- Ambulatory
surgical centers
- Other
Regional Outlook (Revenue, USD Billion;
2020-2028)
- North
America
- Europe
- Asia
Pacific
- Latin
America
- Middle
East & Africa
Get
TOC of this Report @ https://www.reportsanddata.com/report-detail/diabetic-retinopathy-market/toc
Thank you for reading our
report. Get in touch with us to know more about the customization feature and
our team with provide you the best suited report as per your need.
About Us:
Reports and Data is a market research and consulting
company that provides syndicated research reports, customized research reports,
and consulting services. Our solutions purely focus on your purpose to locate,
target and analyze consumer behavior shifts across demographics, across
industries and help client’s make a smarter business decision. We offer market
intelligence studies ensuring relevant and fact-based research across a
multiple industries including Healthcare, Technology, Chemicals, Power and
Energy. We consistently update our research offerings to ensure our clients are
aware about the latest trends existent in the market.
Contact Us:
John W
Head of Business Development
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Reports and Data | Web: www.reportsanddata.com
Comments
Post a Comment